All Episodes

RhAPPcast: Identification and Diagnosis of XLH: A Story of Family History

Medication Review: What Is the Safety Profile of Tirzepatide?

Medication Review: Tirzepatide Starting Dose & Titration for Optimal Outcomes

Journal Club Review: SOLSTICE Publication

FAQ: How Can HPP Be Misdiagnosed in Rheumatology and What Are Common Diagnostic Pitfalls?

Medication Review: Describe The Mechanism of Action of Tirzepatide

Journal Club Review: APEX Publication

RhAPPcast: Diagnostic Crossroads: Clues, Pitfalls, and the Journey to an HPP Diagnosis

Journal Club Review: The Challenge of Hypophosphatasia Diagnosis in Adults

FAQ: How Does Weight Reduction Impact PsA Outcomes?

FAQ: What Are the Neuromuscular and Functional Burdens of Living With HPP?

RhAPPcast: IVIG Unpacked

Journal Club Review: DISCOVER-2 Severe PsA Publication

FAQ: How Does Obesity Affect PsA Outcomes?

FAQ: What Skeletal and Dental Manifestations Might Indicate HPP?

RhAPPcast: SubQ Solutions: Induction and Maintenance in Moderately to Severely Active CD and UC

RhAPPcast: Upadacitinib in GCA: Interpreting the 2-Year SELECT-GCA Results

FAQ: What is the Importance of MRI in Assessing Axial Disease Manifestations in PsA?

FAQ: How Does Obesity Impact the Immune System?

FAQ: What Role Does Power Doppler Ultrasound Play in Detecting Subclinical Inflammation/Enthesitis?

RhAPPcast: Unpacking the Genetics: Low ALP

FAQ: What Is the Efficacy of Switching MOA to Guselkumab After Inadequate Response to a single TNFi?

Podcast: Inflammation Intersection: A Rheum-Gi Dialogue

RhAPPcast: Protecting Joints: Inhibiting Structural Damage in PsA With Guselkumab

FAQ: How Can Clinicians Best Approach Talking to Patients With PsA About Weight Management?

Med Review: What is the Safety and Efficacy Profile of Guselkumab in Juvenile Psoriatic Arthritis?

Medication Review: Anti-Drug Antibody Development With Guselkumab in Psoriasis, PsA & IBD

FAQ: What Role Does Tissue-Nonspecific Alkaline Phosphatase (TNSALP) Play in HPP?

Medication Review: Laboratory Monitoring for Guselkumab in Psoriasis, PsA, and IBD

Podcast: Inflammation Amplified: Understanding the PsA—Obesity Connection

Medication Review: Safety and Efficacy of Guselkumab in Crohn’s Disease and Ulcerative Colitis

Across The Rheum Podcast: Part 3 - Clinical Utility and Positioning of IL-23 Agents

Podcast: Under the Surface: Exploring the HPP Diagnosis in Adulthood

FAQ: Screening Tools APPs Use to Identify PsA, SpA, or IBD and Refer Early

FAQ: What Validated Screening Tools Identify PsA/SpA or IBD for Rheumatology or GI Referral?

Across The Rheum Podcast: Part 2 - Currently Available IL-23 Agents

Journal Club: HPP Diagnosis—Current State of the Art & Proposed Criteria for Children and Adults

Med Review: What is the Safety and Efficacy Profile of Guselkumab in Juvenile Psoriatic Arthritis?

Across The Rheum Podcast: Part 1: Immunology of IL-23

RhAPPcast: Born with Burden: Understanding the Pediatric Presentation of HPP

RhAPPcast: Unpacking the Differences: IL-23 Inhibitors in Focus

FAQ: What is Hypophosphatasia and How Does It Present Across the Lifespan?

Journal Club: Guselkumab Binds To CD64+ IL-23–Producing Myeloid Cells to Neutralize IL-23 Signals

FAQ: How Is Hypophosphatasia Diagnosed and What Are the Key Laboratory Markers?

What Is the Correlation of CD64 and IL-23 Expression in Inflamed Joint, Skin, and Gut Tissue?

FAQ: What is the Normal Role of CD64 in Innate and Adaptive Immunity?

Podcast: A Tale of Two Pediatric APPs

Medication Review: Describe the Dual Mechanism of Action of Guselkumab

FAQ: Why is the mvdH-S Score Used Most Often in PsA Trials?

FAQ: How Does The Design of APEX Differ From DISCOVER-2 To Enrich For Structural Damage?

The Conversation That Matters: Talking to Patients About Obesity and IMIDs

From Insight to Action: Practical Strategies to Improve Outcomes in Patients with Obesity and IMIDs

The Hidden Costs: Obesity’s Role in Suboptimal Outcomes and Healthcare Burden in IMIDs

Obesity and IMIDs: Unpacking the Epidemic and Its Far-Reaching Impacts

Live from RhAPP National: ILD & PH-ILD at the Rheum–Pulm Crossroads

RhAPPcast: ANCA-Associated Vasculitis: Insights From the RhAPP National Conference

FAQ: What is the clinical significance of structural damage in PsA?

Medication Review: Evidence for Guselkumab in Preventing Structural Damage Progression

RhAPPcast: Beyond Dryness: Key Takeaways from the Sjögren’s Symposium at RhAPP 2025

FAQ: What is the Effect of Guselkumab on Structural Damage in PsA?

FAQ: What is the Inflation Reduction Act & How Does It Impact Affordability of Biologic Therapies?

RhAPPcast: Unmasking XLH: Misdiagnosed and Misunderstood

RhAPPcast: Refractory PMR: When Steroids Aren’t Enough – Unmet Needs in Treatment

RhAPPcast: The Safety Conversation: Upadacitinib in the Treatment of GCA

Medication Review: What is the safety profile of sarilumab in PMR & RA?

RhAPPcast: Expanding the Arsenal: JAK Inhibitors in the Evolving GCA Landscape

Medication Review: How is Sarilumab Dosed & Administered for the Treatment of PMR & RA?

Medication Review: Key Patient Education When Starting Sarilumab for PMR or RA

RhAPPcast: Inside the Evidence: A Deep Dive into the SELECT-GCA Study

RhAPPcast: Laying the Foundation: Historical Approaches to GCA Treatment

FAQ: What is the Role of Sarilumab in Managing PMR?

Journal Club: Comparative Effectiveness of Sarilumab vs. Methotrexate as a Corticosteroid-Sparing Agent in Patients with Polymyalgia Rheumatica

FAQ: Choosing Between Steroid-Sparing Agents in PMR Treatment

Medication Review: Leflunomide Medication Review

RhAPPcast: Spotting the Signs: Recognizing and Diagnosing Giant Cell Arteritis

RhAPPcast: Foundations of PMR: Diagnosis, First-Line Therapy, and Tapering Strategies

Journal Club Review: Sarilumab for Relapse of Polymyalgia Rheumatica During Glucocorticoid Taper

FAQ: Steroid-Sparing Agent Consideration in PMR Management & What Options Are Available?

FAQ: What Are the Most Recent Treatment Guidelines for PMR, and What Are the Key Clinical Takeaways?

Medication Review: What is the Mechanism of Action of Methotrexate?

Journal Club Review: A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis

RhAPPcast: Understanding the TYK2/STAT Signaling Pathway in PsA: Clinical Implications and Beyond

Medication Review: Hydroxychloroquine Medication Review

FAQ: How Does the Selectivity of TYK2 and JAK Enzyme Inhibition Influence Their Safety Profiles

FAQ: According to the New 2024 ACR Guidelines for Lupus Nephritis, How Do You Monitor LN?

FAQ: Can You Recapture Response to IL-17i Therapy After Interruption or Discontinuation in Therapy?

FAQ: Steroid Tapering in Lupus Nephritis: Insights from the 2024 ACR Guidelines

Medication Review: What Is the Safety Profile of Deucravacitinib in PsO and PsA?

Journal Club Review: Voclosporin in Lupus Nephritis: New Insights on Efficacy & Safety from Clinical Trials

Medication Review: What is the Mechanism of Action of Deucravacitinib?

RhAPPcast: Practical Application: Integrating the New ACR LN Guidelines

Medication Review: What is the Real World Evidence of Guslekumab in PsA

FAQ: TYK2/STAT Pathway & Why TYK2 Therapy Works for Psoriasis and Psoriatic Arthritis

RhAPPcast: Decoding IL-17: Comparing and Contrasting IL-17A and IL-17F Inhibition

Medication Review: What Are the Clinically Meaningful Differences Between Voclosporin and Other Calcineurin Inhibitors?

RhAPPcast: ACR Psoriatic Arthritis RhAPPUp Part 3

RhAPPcast: ACR Psoriatic Arthritis RhAPPUp Part 2

RhAPPcast: ACR Psoriatic Arthritis RhAPPUP Part 1

RhAPPcast: The Relative Persistency and Effectiveness of Guselkumab in the Real-World

Medication Review: What is the safety profile of voclosporin and how should it be monitored?

Journal Club Review: Evaluating the Efficacy of Biologic With and Without Methotrexate

Journal Club Review: Voclosporin for Lupus Nephritis: Efficacy & Safety Insights from AURORA 1 & 2 Trials

Medication Review: Voclosporin Dosing, Administration, Adjustments & Interactions

Medication Review: What is the Efficacy of Guselkumab Across the GRAPPA Domains

FAQ: Are IL-17 Inhibitors Efficacious in Treating the Nail-DIP Complex in PsA?

FAQ: What Are CNIs? Treating Lupus Nephritis with the Latest ACR Guidelines

RhAPPcast: Elevating Care in LN: What the New ACR Guidelines Mean for Patients & How APPs can Apply Them

FAQ: How do IL-23 and IL-17 Inhibitors Differ in Clinical Efficacy

Journal Club Review: Ixekizumab vs. Guselkumab in Plaque Psoriasis (12-Week Trial Results)

Medication Review: What is Voclosporin and How Does it Work?

FAQ: According to the New 2024 ACR Guidelines for LN, What Are the Treatment Goals For Patients With LN?

Journal Club Review: Long-Term Safety of Guselkumab in Patients with Psoriatic Disease

RhAPPcast: Navigating Leflunomide Use in Pregnant Patients with Sjögren’s Syndrome

FAQ: According to the New 2024 ACR Guidelines, How Do You Treat LN?

FAQ: How Do You Interpret cDAPSA/DAPSA and MDA?

FAQ: How Do You Explain The Timing of Ixekizumab's Clinical Efficacy to Patients?

FAQ: 2024 ACR Guidelines: Screening & Diagnosing Lupus Nephritis in SLE Patients

RhAPPcast: LN Updates Unpacked: Insights on New ACR Guidelines

FAQ: How is Lupus Nephritis Defined?

FAQ: How Does Real-World Evidence Differ From Randomized Controlled Trials

FAQ: How Long Has It Been Since the Last ACR LN Guideline Updates, and Why Is This Significant?

Journal Club Review: Effectiveness of Methotrexate and Leflunomide as Corticoid-Sparing Drugs

RhAPPcast :The Clinical Utility of Guselkumab in Axial PsA

Journal Club Review: Efficacy & Safety of Ixekizumab ± Methotrexate in PsA (52-Week SPIRIT-H2H)

FAQ: How Do You Interpret Radiographic Progression Using Modified-vdHS or mTSS?

Medication Review: What Is the Efficacy of Ixekizumab Across the GRAPPA and EULAR Domains?

Medication Review: What Is the Safety Profile of Guselkumab in PsO and PsA?

FAQ: How Does Axial PsA Differ From AS Clinically, Genetically, and Radiographically?

Journal Club Review: 6-Month Guselkumab Effectiveness in PsA (Real-World CorEvitas Data)

RhAPPcast: Navigating the Complexities: IL-17 Inhibitors and IBD Risk

FAQ: Why is Binding CD64+ Important When Discussing IL23 Directed Therapy

Journal Club Review: Upadacitinib Safety & Efficacy in Pediatric JIA (Phase-1 Interim Data)

RhAPPcast: Lost Time: The Impact of Delaying Optimal Therapy in RA & SpA Patients Without Disease Control

Journal Club Review: 5-Year Data on Switching Upadacitinib & Adalimumab in RA

FAQ: Definition of Remission in Rheumatoid Arthritis & Likelihood with Advanced Therapies

Medication Review: How is Guselkumab dosed in PsO, PsA, and IBD

RhAPPcast: Navigating Remission in Rheumatoid Arthritis: Approaches, Advances, Impact, and Insights

FAQ: Variability in JAK Inhibition Specificity & Its Clinical Implications

RhAPPcast: CD64+ Binding Description, Relevance, and Potential Clinical Implications

FAQ: What Is the Difference Between Biosimilars and Generics?

FAQ: What Is the ORAL Surveillance Study and How Can It Be Applied to Clinical Practice?

FAQ: What is the Safety Profile of Ixekizumab in PsA and axSpa

Medication Review: What Is the Safety Profile of Upadacitinib Across Indications?

FAQ: Provide Immunologic Rationale For IL23 Directed Therapy in PsA, PsO, and IBD.

RhAPPcast: Biosimilars and The Patient Perspective

Medication Review: How Is Upadacitinib Dosed Across Rheumatologic Indications?

FAQ: Provide Immunologic Rationale for JAK-Directed Therapy in Rheumatic Disease

Medication Review: Describe the Mechanism of Action of Upadacitinib

FAQ: Provide Immunologic Rationale For IL17-Directed Therapy in PsA, AS, and nr-axSpA

FAQ: Describe the IL17-Induced Inflammatory Cascade

FAQ: Describe JAK-STAT Signaling in Inflammation

FAQ: What Does It Mean for a Biosimilar to Be Interchangeable and Why Is That Important?

Journal Club Review: Long-Term Efficacy and Safety of Guselkumab

Medication Review: What is Non-Responder Imputation and How is it Utilized in Clinical Trials

RhAPPcast: Biosimilars Unveiled - Empowering APPs for Better Patient Conversations

Medication Review: Describe The Mechanism of Action of Ixekizumab

FAQ: What is The Role of IL23/IL17 Axis in Rheumatic Disease

RhAPPcast: The IL23/IL17 Cascade and Implications in the Pathogenesis of PsA, PsO, and IBD

The 2024 RhAPP National Conference in Nashville, TN

FAQ: Describe The IL23/IL17 Axis

Journal Club Review: Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

Medication Review: Describing the Mechanism of Action of Guselkumab

FAQ: Define, compare, and contrast humoral and cell-mediated immunity.

RhAPPcast Spotlight: Clinical Cornerstones with Lindsay Tom, PA-C

RhAPPcast Spotlight: Clinical Cornerstones with Cayla Alexander, DNP, ARNP

Breathing New Life: HRCT and PFTs in ILD with Corinne Young of APAPP

Spotlight: Clinical Cornerstones, Mary Elliott, PA-C

Leading the Way: Dr. John Cush on Rheumatology Leadership

Discussing Biosimilars With Patients

The Nocebo Effect

Voices for Change: Madelaine Feldman, MD of CSRO on Advocacy in Rheumatology

The Practical Use of Biosimilars in Gastroenterology APP Practice

The Practical Use of Biosimilars in Rheumatology APP Practice

The Benefits of Biosimilars

Managed Care and Biosimilars

Interchangeability & Switching of Biosimilars

Spotlight: Clinical Cornerstones, Daric Mueller, MS, PA-C

Biosimilar Extrapolation

The Difference Between Biosimilars & Generic Drugs

The Regulatory Pathway to Biosimilar Approval

Development of Biosimilars

From Idea to Impact: The RhAPP Origin Story

Biosimilars Series: What Are Biosimilars?